COVID-19 in orthotopic heart transplant recipients and association with donor specific antibodies.
Transpl Immunol
; 75: 101712, 2022 12.
Article
in English
| MEDLINE | ID: covidwho-2028552
ABSTRACT
De novo donor-specific antibodies (DSAs) are associated with increased risk of antibody-mediated rejection and worse clinical outcomes after orthotopic heart transplant (OHT). No study has reported the production of DSAs after infection by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in an OHT population. In this retrospective study, we described coronavirus disease 2019 (COVID-19) incidence and clinical course in a large, contemporary OHT cohort. We showed that the case-fatality rate has significantly decreased since the early days of the pandemic, although remains higher than that of the general population. In addition, we found that 10% of OHT recipients developed de novo DSAs or experienced an increase in pre-existing DSAs after COVID-19, with the majority occurring in unvaccinated patients (15% vs 2%). Further studies are necessary to substantiate our findings in an external cohort.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Heart Transplantation
/
COVID-19
Type of study:
Cohort study
/
Observational study
/
Prognostic study
Limits:
Humans
Language:
English
Journal:
Transpl Immunol
Journal subject:
Allergy and Immunology
/
Transplantation
Year:
2022
Document Type:
Article
Affiliation country:
J.trim.2022.101712
Similar
MEDLINE
...
LILACS
LIS